Cargando…
Diabetes and Second Neoplasia Impact on Prognosis in Pre-Fibrotic Primary Myelofibrosis
SIMPLE SUMMARY: The 2016 WHO-revised classification of MPNs recognized pre-fibrotic PMF (pre-PMF) as a distinct clinical entity from both overt fibrotic PMF (overt PMF) and essential thrombocythemia (ET). In fact, while the initial presentation of pre-PMF is often an isolated thrombocytosis, thus mi...
Autores principales: | Cattaneo, Daniele, Vener, Claudia, Elli, Elena Maria, Bucelli, Cristina, Galli, Nicole, Cavalca, Fabrizio, Auteri, Giuseppe, Vincelli, Donatella, Martino, Bruno, Gianelli, Umberto, Palandri, Francesca, Iurlo, Alessandra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8997979/ https://www.ncbi.nlm.nih.gov/pubmed/35406571 http://dx.doi.org/10.3390/cancers14071799 |
Ejemplares similares
-
An unusual type of myeloid sarcoma localization following myelofibrosis: A case report and literature review
por: Orofino, Nicola, et al.
Publicado: (2017) -
Trend of circulating CD34(+) cells in patients with myelofibrosis: Association with spleen response during ruxolitinib treatment
por: Iurlo, Alessandra, et al.
Publicado: (2022) -
P1018: TREND OF CIRCULATING CD34+ CELLS IN MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB
por: Cattaneo, D., et al.
Publicado: (2022) -
Successful Imatinib Treatment for Systemic Mastocytosis Associated With Myelodysplastic/Myeloproliferative Neoplasm: Report of a Case and Literature Review
por: Barozzi, Enrico, et al.
Publicado: (2022) -
Treatment of Myelofibrosis: Old and New Strategies
por: Iurlo, Alessandra, et al.
Publicado: (2017)